title: Editorial: can we afford the new direct-acting anti-virals for treatment of genotype 1 hepatitis C? Authors' reply.
authors.affiliation: Departments of Medicine and Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. ssaab@mednet.ucla.edu.
authors.forename: S
authors.initials: S
authors.lastname: Saab
authors.forename: Z M
authors.initials: ZM
authors.lastname: Younossi
mesh_terms: D000998:Antiviral Agents / Q000191:economics*; D019698:Hepatitis C, Chronic / Q000191:economics*; D006801:Humans; D016898:Interferon-alpha / Q000191:economics*; D011092:Polyethylene Glycols / Q000191:economics*; D012254:Ribavirin / Q000191:economics*; D014542:Uridine Monophosphate / Q000031:analogs & derivatives*
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D011092:Polyethylene Glycols; D012254:Ribavirin; D014542:Uridine Monophosphate